Today: 10 June 2026
KLA stock notches new 52-week high as chip-tool shares firm; Susquehanna lifts target
13 January 2026
1 min read

KLA stock notches new 52-week high as chip-tool shares firm; Susquehanna lifts target

New York, Jan 12, 2026, 21:02 ET — Market closed

  • KLA shares jumped 2.0% to close at $1,428.17, hitting a fresh 52-week high.
  • Susquehanna bumped up its price target for KLA to $1,500 from $1,125, maintaining a Neutral rating.

KLA Corp (KLAC.O) shares climbed 2.0% Monday, closing at $1,428.17—a fresh 52-week high that topped the previous peak of $1,406.97 from Jan. 6. Trading volume hit 854,084 shares, below the 50-day average, even as the S&P 500 and Dow finished slightly higher. Applied Materials (AMAT.O) jumped roughly 2.0%, while Lam Research (LRCX.O) added nearly 1.0%, boosting the iShares Semiconductor ETF (SOXX.O) by about 0.5%.

The move is significant since KLA operates in process control—providing tools that inspect and measure wafers to detect defects and boost manufacturing yields. As chipmakers ramp up complexity, errors grow costly quickly, keeping investment in inspection equipment firmly in focus.

The stock now hinges on the upcoming data about orders and customer spending plans. As KLA hits new highs, traders want to see proof that demand isn’t confined to just a few AI-related projects.

Susquehanna bumped its price target on KLA to $1,500 from $1,125 but kept a Neutral rating, TheFly reports. The firm’s channel checks indicate the semiconductor equipment industry is gearing up for roughly $120 billion in wafer fab equipment spending—the machines used to manufacture chips. It also suggested the supply chain might need to prepare for a surge beyond $150 billion as global semiconductor revenue continues to climb.

A raised target absent an upgrade often signals caution. A neutral rating shows the firm isn’t urging a buying spree just yet, despite a more favorable outlook.

Tuesday’s session hinges on KLA staying above the key $1,400 mark and the broader chip-tool sector maintaining momentum. Follow-up target shifts might drive gains, but they risk backfiring if buying interest fades too fast.

Yet the risk is always close: chipmaking moves in cycles, and spending can pivot abruptly. A delay in tool shipments, cuts to capital budgets, or regulatory restrictions on exports can quickly reset expectations.

KLA is set to report its fiscal second-quarter results on Thursday, Jan. 29, after the market closes. The company will host an earnings webcast at 2 p.m. Pacific that same day.

Stock Market Today

  • Apotex Debuts on Toronto Stock Exchange in Largest Life Sciences IPO
    June 10, 2026, 10:06 AM EDT. The Toronto Stock Exchange (TSX) welcomed Apotex Health Corp., marking the largest life sciences initial public offering (IPO) by total proceeds on the exchange, raising $1.3 billion. Apotex, a Canadian global health company, began trading under the symbol APTX on June 11, 2026. The listing reflects the strength of Canadian capital markets and underscores growth in the life sciences sector, which counts 110 companies listed on TSX and TSX Venture Exchange with a combined market capitalization of $26 billion. Apotex provides a wide range of affordable medicines including generics and biosimilars, serving millions worldwide from its Toronto headquarters and global offices. TSX CEO Loui Anastasopoulos praised the listing as showcasing Canadian competitiveness on the global stage.

Latest articles

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

10 June 2026
Rigetti Computing plunged 9.55% to $19.69 Tuesday and dipped further premarket after director Ray O. Johnson filed to sell 122,188 shares worth $2.6 million, testing investor confidence following a recent rally on news of a potential $100 million U.S. Commerce Department quantum-computing award, with traders watching for binding funding terms amid ongoing volatility.
PATH slips again, investors keep questioning AI automation bet

PATH slips again, investors keep questioning AI automation bet

10 June 2026
UiPath shares slid 3.76% to $10.75 and dropped another 1.49% pre-market as investors focused on slowing annual recurring revenue growth—up 12% to $1.901 billion versus 17% revenue growth—raising doubts about AI automation’s impact on recurring sales; second-quarter ARR guidance of $1.929–$1.934 billion is now the key number for PATH’s stock direction.
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal
Previous Story

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread
Next Story

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread

Go toTop